Eupraxia Pharmaceuticals is trading 11.94% down at $5.90 after its August 11, 2026 second-quarter results showed a $14.5 million net loss, up from $8.7 million a year earlier, despite stronger liquidity.

  • Increased research and development spending tied to the expanded RESOLVE trial likely pressured sentiment.
  • Management maintained cash runway into the second half of 2028.
  • The broader market was modestly higher before the August 12 CPI release, pointing to a company-specific earnings reaction rather than overall risk-off trading.